Forbion, a life sciences venture capital firm, led a €75m Series A round in Calluna Pharma, a clinical stage company focused on inflammatory and fibrotic diseases treating, with participation from Sarsia, p53, and Investinor. “Sarsia and p53 strive to bring cutting edge ideas and therapies from early-phase to clinical development and beyond to benefit patients and transform people’s lives. Calluna Pharma epitomizes this, and we are enthusiastic to join forces with Forbion and to contribute to the success of this new entity,” Sveinung Hole, Sarsia Managing Partner and Susanne Stuffers, p53 Managing Partner.